Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Frequently asked questions
What sector does Biosergen AS (BIOSGN) operate in?
Biosergen AS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biosergen AS (BIOSGN) current stock price?
As of the latest data, Biosergen AS stock price is SEK 3.96, with a previous close of SEK 5.45. Biosergen AS lost -SEK 1.49 in the last trading session, representing a -27.34% loss.
What is Biosergen AS (BIOSGN) current market capitalization?
Biosergen AS market cap is approximately 9.30 million.
What is Biosergen AS (BIOSGN) Earnings Per Share (EPS)?
The trailing EPS is -SEK 16.19, and the forward EPS is -SEK 10.00.
Does Biosergen AS (BIOSGN) pay dividends?
No. Biosergen AS does not pay a dividend.
What is Biosergen AS (BIOSGN) beta (volatility) score?
Biosergen AS has a beta of -0.018, indicating lower volatility than the overall market.